Incyte Corp. Stock
€87.28
Your prediction
Incyte Corp. Stock
Pros and Cons of Incyte Corp. in the next few years
Pros
Cons
Performance of Incyte Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Incyte Corp. | -0.970% | 6.232% | 4.302% | 48.435% | 3.633% | 52.962% | 25.294% |
| Regeneron Pharmaceuticals Inc. | -3.920% | 2.652% | -12.607% | 22.556% | -20.039% | -23.807% | 27.522% |
| IQVIA Holdings Inc. | -0.440% | -0.840% | 4.975% | 19.192% | -17.504% | -16.684% | -17.418% |
| Vertex Pharmaceuticals Inc. | -0.230% | 1.870% | 5.249% | -2.834% | -1.966% | 24.453% | 121.428% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Incyte Corporation, trading under the US symbol INCY, is a prominent player in the Biotechnology & Medical Research industry. Investors often look closely at a company’s financials to gauge its health and sustainability. A deep dive into the financial statements of Incyte reveals an intricate picture filled with opportunities and challenges.
A swift glance shows that Incyte has established a robust foundation in the biotech realm. With total assets amounting to approximately $6.78 billion in 2023, the company is on an upward trajectory. In comparison to the total assets of $5.84 billion in 2022 and $4.93 billion in 2021, this marks significant growth, reflecting the company's commitment to expansion and research development. However, the journey is not without its hurdles, with liabilities totaling $1.59 billion against a stockholder equity of $5.19 billion.
When considering Valuation ratios, Incyte appears to be reasonably priced within the market. The trailing PE ratio stands at 156.47, highlighting the market's optimistic expectations; however, the forward PE of 11.6 suggests an anticipated improvement in earnings. The price-to-sales (PS) ratio of 3.1 relative to an enterprise value nearing $9.97 billion suggests that there’s significant valuation based on revenue rather than just earnings potential.
Comments
News
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out
Key Points
- Interested in Incyte Corporation? Here are five stocks we like better.
- Incyte plans to start a Phase 3 trial of mutant CALR antibody 989 in essential thrombocythemia around
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
Key Points
- Interested in Adagene Inc. Sponsored ADR? Here are five stocks we like better.
- Adagene’s lead drug ADG126 (muzastotug) is a masked anti-CTLA-4 antibody designed to improve the
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build
Key Points
- Interested in Incyte Corporation? Here are five stocks we like better.
- Incyte’s CEO says the company’s post-Jakafi growth path is becoming clearer as its commercial business